Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James T Link

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|June 18, 2003
Pharmacological regulation of hepatic glucose productionJames T Link
Cancer Journal (Sudbury, Mass.)|June 25, 2016
Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic ChallengesJames T Link, Michael James Overman
CA: a Cancer Journal for Clinicians|July 7, 2017
The oncologic burden of hepatitis C virus infection: A clinical perspectiveHarrys A Torres, Terri Lynn Shigle, Nassim Hammoudi, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Biaryl amide glucagon receptor antagonistsRavi Kurukulasuriya, Bryan K Sorensen, James T Link, et al.
Journal of Medicinal Chemistry|August 6, 2004
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetesThomas W von Geldern, Noah Tu, Philip R Kym, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetesPeer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Opinion in Investigational Drugs (London, England : 2000)|June 18, 2003
Pharmacological regulation of hepatic glucose productionJames T Link
Cancer Journal (Sudbury, Mass.)|June 25, 2016
Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic ChallengesJames T Link, Michael James Overman
CA: a Cancer Journal for Clinicians|July 7, 2017
The oncologic burden of hepatitis C virus infection: A clinical perspectiveHarrys A Torres, Terri Lynn Shigle, Nassim Hammoudi, et al.
Bioorganic & Medicinal Chemistry Letters|April 15, 2004
Biaryl amide glucagon receptor antagonistsRavi Kurukulasuriya, Bryan K Sorensen, James T Link, et al.
Journal of Medicinal Chemistry|August 6, 2004
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetesThomas W von Geldern, Noah Tu, Philip R Kym, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 24, 2005
Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetesPeer B Jacobson, Thomas W von Geldern, Lars Ohman, et al.
Pageof 1